Sign in
Taking people in United StatesNo phase

Tests a ketogenic diet for blood sugar control in type 1 diabetes

Tests a very-low-carbohydrate diet in adults with type 1 diabetes.

Key facts

Who runs it
Washington University School of Medicine
Where
St Louis, United StatesSee the site
Trial code
Registry title
Efficacy and Safety of a Ketogenic Diet in Type 1 Diabetes
Status
Recruiting
People taking part
58 people, planned
Started
12 Aug 2024
Expected to end
31 Mar 2030
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Ketogenic Diet
  • Standard Diet
Record updated
19 March 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with type 1 diabetes to test whether a very-low-carbohydrate ketogenic diet can safely improve blood sugar control.

Age
18 to 65 years
Sex
All sexes can join.
Disease stage
Type 1 diabetes diagnosed more than 1 year before screening, with HbA1c 7.0% (53 mmol/mol)-9.0% (75 mmol/mol) and eGFR ≥60 mL/min/1.73 m2.
Earlier treatment
Must use an insulin pump or multiple daily injections with a stable insulin method for the past 30 days. Must have used a personal CGM for at least 12 weeks. Cannot take diabetes medicines other than insulin.

Main reasons for not taking part

  • Body mass index <20.0 or >34.9 kg/m2
  • Pregnant, breastfeeding, or planning pregnancy within the 6-month study
  • Diabetes-related hospitalization within 12 months of screening
  • Already eating a low-carbohydrate diet (<130 g/day)
  • Severe gastroparesis, bariatric surgery, or active eating disorder

The registry criteria, word for word

Show all 29 criteriaShow less

Who can take part

  • Age ≥18 and ≤65 years
  • T1D diagnosed >1 year prior to screening
  • HbA1c 7.0%-9.0%
  • Stable insulin delivery method for the past 30 days
  • Ability to read all device instructions and insulin pump settings
  • eGFR ≥60 mL/min/1.73 m2
  • Use of an insulin pump or insulin delivery by multiple daily injections
  • Use of personal CGM for at least 12 weeks and willing to change to Dexcom CGM for the duration of the study, if using a different sensor, to reduce variability in glucose values associated with different CGM products
  • Use of cellular phone with data capability for wireless connectivity to the CGM system

Who cannot take part

  • Active tobacco use (>8 cigarettes/day) or illegal drug use
  • Use of medications known to affect the study outcome measures or increase the risk of study procedures that cannot be temporarily discontinued for this study
  • Severe gastroparesis or history of bariatric surgery
  • Diabetes-related hospitalization (including for diabetic ketoacidosis or severe hypoglycemia) within 12 months of screening
  • Poorly controlled hypertension (SBP ≥160 mmHg or DBP ≥100 mmHg)
  • Taking diabetes medications, other than insulin (particularly SGLT2 inhibitors, which are associated with an increased risk of euglycemic DKA)
  • Significant organ system dysfunction (e.g., severe pulmonary, renal, hepatic, or cardiovascular disease)
  • Major psychiatric illness
  • Active eating disorder
  • Dietary restrictions incompatible with a very-low-carbohydrate KD, vegan diet, vegetarian diet, severe lactose intolerance, severe aversion/sensitivity to eggs, fish, nuts, wheat, or soy, and any anaphylactic food allergy
  • Anemia (Hgb <10 g/dL)
  • Body mass index <20.0 or >34.9 kg/m2
  • Structured exercise >210 minutes per week
  • Pregnant, lactating, not using effective birth control if premenopausal, or planning to become pregnant within the 6-month study period
  • Unstable weight (>4% change in the last 2 months)
  • Regular alcohol consumption (>10 standard drinks per week)
  • Familial hypercholesterolemia
  • Already consuming a low-carbohydrate (<130 g/day) diet
  • Persons who are not able to grant voluntary informed consent
  • Persons who are unable or unwilling to follow the study protocol or who, for any reason, the research team considers an inappropriate candidate for the study

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 65 years old?

Where in United States

  • Washington University School of MedicineSt Louis, United StatesContact: Tara Wilmot, RDNTaking people

About the trial

What the trial wants to find out

Despite strong evidence that tight control of blood sugar reduces the risk of diabetes complications, most people with type 1 diabetes do not achieve recommended blood sugar targets. This randomized controlled trial will test whether a very-low- carbohydrate ketogenic diet can effectively and safely improve blood sugar control in adults with type 1 diabetes.

The 2 groups in the trial

  • Ketogenic DietTreatment being tested

    The Ketogenic Diet group will consume a very-low carbohydrate diet (\<50 g/day) diet. Participants will receive isocaloric packed-out meals for 12 weeks.

  • Standard CareExisting treatment, for comparison

    The Standard Care group will consume a diet consistent with the guidelines recommended by the American Diabetes Association that is high in non-starchy vegetables and lean protein sources and low in added sugar. Participants will receive isocaloric packed-out meals for 12 weeks.

    Treatment: Standard Diet

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Efficacy and Safety of a Ketogenic Diet in Type 1 Diabetes
Plain-language title
Tests a ketogenic diet for blood sugar control in type 1 diabetesGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Fit questions
Built from NCT06503809, who can take part
Record updated
19 March 2026